Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Pfizer is the lead sponsor of 194 current clinical trials in our USA, China, UK, India, Ireland and EU (CTIS) registers. 97 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are PF-08634404, PF-08653944 and Elranatamab. The most-studied condition is Breast Cancer.

Company profiles on this site (news, sites, medicines, approvals): Pfizer Ireland (IE) →Pfizer (US) →

ClinicalTrials.gov trials by status

Recruiting9754%
Not yet open74%
Active, closed7542%

Trials by phase

Phase 37240%
Phase 13017%
Observational2615%
Phase 22615%
Phase 1/2127%
Phase 484%
Phase 2/353%

Clinical trials sponsored by Pfizer

179 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections NCT05639647 · Gram-negative Bacterial Infections	Phase 2	Recruiting	2023-04	USA, India, China
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965 · Breast Cancer Drugs: Everolimus, Exemestane, Fulvestrant	Phase 3	Recruiting	2025-08	UK, USA, India, China
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue NCT06989437 · Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma	Phase 2/3	Recruiting	2025-10	UK, USA, India, China
A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20 NCT07792941 · Healthy	Phase 1	Recruiting	2026-08	USA
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. NCT06629779 · Metastatic Castration-Resistant Prostate Cancer Drugs: Enzalutamide, Mevrometostat	Phase 3	Recruiting	2024-10	UK, USA, China
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B NCT05611801 · ClinicalTrials.gov ↗ · Hemophilia A, Hemophilia B Drug: Marstacimab	Phase 3	Recruiting	2022-12	UK, USA, India, China
A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults NCT07768345 · Respiratory Syncytial Virus (RSV)	Phase 3	Recruiting	2026-08	USA
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema NCT07216027 · Atopic Dermatitis, Eczema, Atopic Drug: PF-08049820	Phase 2	Recruiting	2025-11	USA, China
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A. NCT06703606 · ClinicalTrials.gov ↗ · Severe Hemophilia A Drug: Marstacimab	Phase 1	Recruiting	2025-05	USA, India
A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF NCT07653100 · ClinicalTrials.gov ↗ · Respiratory Syncytial Virus (RSV) Drug: RSVpreF	Phase 3	Recruiting	2026-06	India
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors NCT05145127 · ClinicalTrials.gov ↗ · Hemophilia A, Hemophilia B	Phase 3	Recruiting	2021-11	UK, USA, India, China
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH) NCT06462235 · ClinicalTrials.gov ↗ · Gram-negative Bacterial Infection	Phase 2	Recruiting	2024-09	USA, India
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease NCT07363694 · ClinicalTrials.gov ↗ · Moderate to Severe Chronic Obstructive Pulmonary Disease	Phase 2/3	Recruiting	2026-02	USA, India, China
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer NCT07222800 · Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms Drugs: Bevacizumab, PF-08634404	Phase 3	Recruiting	2025-12	USA, China
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies NCT06698796 · ClinicalTrials.gov ↗ · Dermatomyositis, Polymyositis	Phase 3	Recruiting	2025-01	USA, India, China
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments NCT05020236 · Multiple Myeloma Drugs: Daratumumab, Dexamethasone, Elranatamab	Phase 3	Recruiting	2021-10	UK, USA, China
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies NCT07160244 · Healthy Drug: 20-valent pneumococcal conjugate vaccine	Phase 3	Recruiting	2025-08	UK, USA
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) NCT07144280 · ClinicalTrials.gov ↗ · Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma Drugs: Docetaxel, PF-08046054	Phase 3	Recruiting	2025-09	UK, USA, India, China
A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring NCT05721937 · Atopic Dermatitis Drug: Abrocitinib	Observational	Recruiting	2023-07	USA
A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India NCT07685769 · ClinicalTrials.gov ↗ · Acute Treatment of Migraine	Phase 4	Recruiting	2026-07	India
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine NCT04743141 · Acute Treatment of Migraine Drug: Rimegepant	Phase 3	Recruiting	2021-04	USA
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD NCT05431088 · ClinicalTrials.gov ↗ · Sickle Cell Disease	Phase 2/3	Recruiting	2022-09	UK, USA, India
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine NCT06641466 · ClinicalTrials.gov ↗ · Menstrual Migraine Drug: Rimegepant	Phase 3	Recruiting	2025-03	UK, USA, India, China
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] NCT05895786 · ClinicalTrials.gov ↗ · Myositis	Phase 3	Recruiting	2023-05	UK, USA, India, China
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT07222566 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung Drugs: Pembrolizumab, PF-08634404	Phase 3	Recruiting	2026-01	USA, India, China
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis NCT06398626 · Colitis, Ulcerative Drug: Etrasimod	Observational	Recruiting	2024-09	USA
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. NCT06758401 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC) Drugs: Pembrolizumab, Sigvotatug vedotin	Phase 3	Recruiting	2025-07	UK, USA, India, China
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema NCT06807268 · Eczema Drug: Abrocitinib	Phase 3	Recruiting	2025-07	USA, China
A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease NCT07677358 · Hepatic Impairment, Healthy, Hepatic Insufficiency, Healthy Adults Drug: Atirmociclib	Phase 1	Recruiting	2026-06	USA
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia NCT05070845 · ClinicalTrials.gov ↗ · Primary Immune Thrombocytopenia	Phase 2	Recruiting	2022-02	UK, USA
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis NCT07470879 · ClinicalTrials.gov ↗ · Colitis, Ulcerative Drug: Etrasimod	Phase 2	Recruiting	2026-05	UK, USA
A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India. NCT06587035 · ClinicalTrials.gov ↗ · Dwarfism, Pituitary Drug: Somatrogon	Observational	Recruiting	2025-01	India
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose NCT06866405 · RSV Infection Drug: RSVpreF	Phase 3	Recruiting	2025-04	USA
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant NCT05046613 · Migraine	Observational	Recruiting	2021-09	USA
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials NCT05203172 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 4	Recruiting	2022-07	UK, USA
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors NCT07090499 · ClinicalTrials.gov ↗ · Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma	Phase 1	Recruiting	2025-08	UK, USA, China
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer NCT07392892 · Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer Drugs: Nivolumab, PF-08634404	Phase 2/3	Recruiting	2026-05	USA, China
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) NCT06152575 · ClinicalTrials.gov ↗ · Multiple Myeloma Drugs: Bortezomib, Carfilzomib, Dexamethasone	Phase 3	Recruiting	2024-02	UK, USA, China
Randomized Study in Children and Adolescents With Migraine: Acute Treatment NCT04649242 · ClinicalTrials.gov ↗ · Pediatric Migraine	Phase 3	Recruiting	2021-01	UK, USA, China
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata. NCT07029828 · ClinicalTrials.gov ↗ · Severe Alopecia Areata Drugs: Ritlecitinib higher, Ritlecitinib lower	Phase 3	Recruiting	2025-09	USA, China
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. NCT07028853 · ClinicalTrials.gov ↗ · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer Drugs: Enzalutamide, Mevrometostat	Phase 3	Recruiting	2025-09	UK, USA, China
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older NCT07282665 · ClinicalTrials.gov ↗ · Clostridoides Difficile Associated Disease	Phase 3	Recruiting	2025-12	UK, USA
A Study to Learn About mRNA Vaccines Against Influenza in Adults NCT07431853 · ClinicalTrials.gov ↗ · Healthy Adults	Phase 2	Recruiting	2026-02	USA
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma NCT06977581 · ClinicalTrials.gov ↗ · Asthma Drug: PF-07275315	Phase 2	Recruiting	2025-05	UK, USA, China
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants NCT07573462 · ClinicalTrials.gov ↗ · Pneumococcal Disease Drugs: 20-valent pneumococcal conjugate vaccine, PG4	Phase 3	Recruiting	2026-05	USA
A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML). NCT06297161 · ClinicalTrials.gov ↗ · Chronic Leukemia Myelogenous	Observational	Recruiting	2025-01	USA
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant NCT05623020 · ClinicalTrials.gov ↗ · Multiple Myeloma Drugs: Bortezomib, Daratumumab, Dexamethasone	Phase 3	Recruiting	2022-11	UK, USA, China
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer NCT07227415 · ClinicalTrials.gov ↗ · Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer Drugs: Axitinib, Casdatifan, Ipilimumab	Phase 1/2	Recruiting	2026-02	USA, China
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer NCT07206225 · ClinicalTrials.gov ↗ · Non-muscle Invasive Bladder Cancer	Phase 1	Recruiting	2025-11	UK, USA
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease NCT05261139 · ClinicalTrials.gov ↗ · COVID-19 Drug: Ritonavir	Phase 3	Recruiting	2022-03	UK, USA
Study of PF-07248144 in Advanced or Metastatic Solid Tumors NCT04606446 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer Drugs: Fulvestrant, Letrozole, Palbociclib	Phase 2	Recruiting	2020-11	USA, China
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC NCT07489066 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC) Drug: PF-08634404	Phase 2	Recruiting	2026-06	USA, China
A Study to Learn How Different Amounts of the Study Medicine Called PF-08642534 Are Tolerated and Act in the Body of People Who Have Obesity NCT07731139 · ClinicalTrials.gov ↗ · Obesity	Phase 1	Recruiting	2026-07	USA
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata NCT06873945 · ClinicalTrials.gov ↗ · Alopecia Areata Drug: Ritlecitinib	Phase 3	Recruiting	2025-04	UK, USA, China
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) NCT06991257 · ClinicalTrials.gov ↗ · Heart Failure Drugs: Medium, PF-07328948	Phase 2	Recruiting	2025-06	UK, USA, China
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma NCT03460977 · ClinicalTrials.gov ↗ · Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL) Drugs: Enzalutamide, Itraconazole, Mevrometostat	Phase 1	Recruiting	2018-04	USA, China
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised NCT07013474 · ClinicalTrials.gov ↗ · COVID-19 Infection Drugs: Ibuzatrelvir, Remdesivir	Phase 3	Recruiting	2025-07	USA
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively NCT05568719 · ClinicalTrials.gov ↗ · Hemophilia A, Hemophilia B	Phase 3	Recruiting	2022-12	USA
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function NCT07269301 · ClinicalTrials.gov ↗ · Hepatic Impairment, Healthy Drug: PF-07328948	Phase 1	Recruiting	2025-12	USA
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis NCT05995964 · ClinicalTrials.gov ↗ · Atopic Dermatitis Drug: PF-07275315	Phase 2	Recruiting	2023-08	USA, China
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease NCT06679140 · ClinicalTrials.gov ↗ · COVID-19 SARS-CoV-2 Infection Drug: Ibuzatrelvir	Phase 3	Recruiting	2024-12	USA, China
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema NCT07765888 · ClinicalTrials.gov ↗ · Atopic Dermatitis Drug: Tilrekimig	Phase 3	Recruiting	2026-08	USA
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer NCT07421700 · ClinicalTrials.gov ↗ · Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma Drugs: Enfortumab Vedotin, PF-08634404	Phase 1/2	Recruiting	2026-03	USA, China
A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function NCT07231991 · ClinicalTrials.gov ↗ · Healthy Participants Drug: Vepdegestrant	Phase 1	Recruiting	2025-11	USA
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema NCT06807281 · ClinicalTrials.gov ↗ · Atopic Dermatitis Drug: Abrocitinib	Phase 3	Recruiting	2025-12	USA, China
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer NCT06952660 · ClinicalTrials.gov ↗ · Cervical Cancer Drug: Tivdak	Phase 4	Recruiting	2025-05	USA
A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults NCT07794748 · ClinicalTrials.gov ↗ · Pneumococcal Disease Drug: 20-valent pneumococcal conjugate vaccine	Phase 3	Recruiting	2026-09	USA
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer NCT07226999 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC) Drugs: Atezolizumab, PF-08634404	Phase 2/3	Recruiting	2025-12	USA, China
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants. NCT07629440 · ClinicalTrials.gov ↗ · Pneumococcal Disease Drugs: 20-valent pneumococcal conjugate vaccine, PG4	Phase 3	Recruiting	2026-05	USA
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis NCT05287126 · ClinicalTrials.gov ↗ · Ulcerative Colitis Drug: Etrasimod	Phase 2	Recruiting	2022-12	USA
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata NCT07733765 · ClinicalTrials.gov ↗ · Alopecia Areata Drug: Ritlecitinib	Phase 3	Recruiting	2026-07	USA
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients NCT06564389 · ClinicalTrials.gov ↗ · Healthy Participants, Atopic Dermatitis	Phase 1	Recruiting	2024-11	USA
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. NCT07227012 · ClinicalTrials.gov ↗ · Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma Drugs: Ipilimumab, PF-08634404	Phase 1/2	Recruiting	2025-12	USA
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity NCT07595549 · ClinicalTrials.gov ↗ · Obesity, Overweight and/or Obesity, Overweight Drug: PF-08653944	Phase 3	Recruiting	2026-06	USA
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. NCT07219615 · ClinicalTrials.gov ↗ · Chronic Spontaneous Urticaria Drug: Ritlecitinib	Phase 2	Recruiting	2025-10	USA, China
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting NCT05452941 · ClinicalTrials.gov ↗ · Pneumonia	Observational	Recruiting	2022-10	USA
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine NCT07609914 · ClinicalTrials.gov ↗ · Acute Treatment of Migraine Drug: Rimegepant	Phase 4	Recruiting	2026-05	USA
Phase 1 Study of PF-08046033 in Advanced Solid Tumors NCT07519655 · ClinicalTrials.gov ↗ · Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma	Phase 1	Recruiting	2026-04	USA
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. NCT06899204 · ClinicalTrials.gov ↗ · Atopic Dermatitis, Atopic Dermatitis, Unspecified, Dermatitis, Atopic Drug: Abrocitinib	Observational	Recruiting	2026-04	USA
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine NCT06995729 · ClinicalTrials.gov ↗ · Acute Treatment of Migraine	Phase 1	Recruiting	2025-05	USA
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes NCT06924320 · ClinicalTrials.gov ↗ · Obesity and Obesity-related Medical Conditions Drug: PF-08653944	Phase 1/2	Recruiting	2025-03	USA
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers NCT07227298 · ClinicalTrials.gov ↗ · Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer Drugs: PF-08634404, Sigvotatug vedotin	Phase 1/2	Recruiting	2026-01	USA, China
A Study to Learn About a Vaccine Against E Coli in Healthy Adults NCT07122986 · ClinicalTrials.gov ↗ · Healthy Participants	Phase 1	Recruiting	2025-08	USA
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma NCT07660731 · ClinicalTrials.gov ↗ · Healthy Volunteer Study, Healthy Adults, Healthy Participants Drug: Midazolam	Phase 1	Recruiting	2026-06	USA
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer NCT07476287 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer Drug: PF-08634404	Phase 2	Recruiting	2026-07	USA, China
An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers NCT07426757 · ClinicalTrials.gov ↗ · Advanced Malignancies, Advanced Cancer Drug: Midazolam	Phase 1	Recruiting	2026-07	USA
A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults NCT07597928 · ClinicalTrials.gov ↗ · Healthy Adults, Healthy Drugs: PF-08049820, Rabeprazole	Phase 1	Recruiting	2026-05	USA
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function NCT07315360 · ClinicalTrials.gov ↗ · Renal Impairment, Healthy Drug: PF-07328948	Phase 1	Recruiting	2026-01	USA
Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents NCT07660198 · ClinicalTrials.gov ↗ · Pneumococcal Disease Drugs: 20-valent pneumococcal conjugate vaccine, PG4	Phase 3	Recruiting	2026-06	USA
A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function NCT07519135 · ClinicalTrials.gov ↗ · Healthy Drug: PF-08653944	Phase 1	Recruiting	2026-04	USA
A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine NCT07500506 · ClinicalTrials.gov ↗ · Lyme Disease Drug: VLA15	Phase 3	Recruiting	2026-04	USA
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805 · ClinicalTrials.gov ↗ · Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer Drugs: Bevacizumab, Cetuximab, Fluorouracil	Phase 1	Recruiting	2025-12	USA
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects NCT05156398 · ClinicalTrials.gov ↗ · Migraine Drug: Rimegepant	Phase 3	Recruiting	2022-02	USA
A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine NCT07729462 · ClinicalTrials.gov ↗ · Preventive Treatment of Migraine Drug: Rimegepant	Phase 3	Recruiting	2026-08	USA
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) NCT06057402 · ClinicalTrials.gov ↗ · Multiple Myeloma Drug: Elranatamab	Phase 4	Recruiting	2023-10	USA, China
A Study to Learn About the Safety of PENBRAYA During Pregnancy NCT07768163 · ClinicalTrials.gov ↗ · Meningococcal Disease	Observational	Recruiting	2024-05	USA
A Study to Evaluate 20vPnC in Healthy Chinese Infants NCT07754539 · ClinicalTrials.gov ↗ · Pneumococcal Diseases	Phase 3	Recruiting	2026-07	China
A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma NCT07772921 · ClinicalTrials.gov ↗ · Asthma Drug: Tilrekimig	Phase 3	Not yet open	2026-08	USA
A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults NCT07819097 · ClinicalTrials.gov ↗ · Adult, Healthy Participants Drug: RSVpreF	Phase 3	Not yet open	2026-09	USA, China
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema NCT07783425 · ClinicalTrials.gov ↗ · Atopic Dermatitis Drugs: Dupilumab, Tilrekimig	Phase 3	Not yet open	2026-08	USA

Showing the 100 most recently updated of 179 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Pfizer in the EU trials register (CTIS)

15 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System with Pfizer as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
C6461010 - An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-08634404 Monotherapy or in Combination in Adult Participants with Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer 2025-524825-42-00 · Neoplasms Drugs: Carboplatin, Paclitaxel, Pemetrexed	Phase 2	Authorised	Ireland + 5 more
A Study to Learn About the Study Medicine Called PF-08032562 in People with Advanced or Metastatic Solid Tumors 2025-524387-38-00 · Neoplasms	Phase 1	Authorised	France, Spain
C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6) 2026-525318-75-00 · Nutritional and Metabolic Diseases Drug: PF-08653944	Phase 3	Authorised	Spain, France, Germany + 2 more
C4931007 - A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS 2025-523447-35-02 · Bacterial Infections and Mycoses	Phase 3	Authorised	Spain, Finland, Poland + 4 more
Phase 1 Study of PF-08046033 in Advanced Solid Tumors 2025-522532-14-00 · Neoplasms	Phase 1	Authorised	Netherlands, France, Spain
C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer 2025-524686-24-00 · CTIS ↗ · Neoplasms Drugs: Carboplatin, Etoposide, PF-08634404	Phase 2	Ongoing	France, Italy, Spain
A Study to Learn How Different Amounts of the Study Intervention Called PF-07832837 are Tolerated and Act in the Body in Healthy Adults and Patients 2025-524150-34-00 · CTIS ↗ · Skin and Connective Tissue Diseases	Phase 1	Authorised	Poland
C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 2024-518587-12-00 · CTIS ↗ · Respiratory Tract Diseases Drug: PF-07275315	Phase 2	Ongoing	Spain, Germany, Poland + 6 more
C0371017 - A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY 2025-523660-21-00 · CTIS ↗ · Hemic and Lymphatic Diseases	Phase 3	Ongoing	Italy, Germany, France + 3 more
C6231002 - A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS 2025-522965-31-00 · CTIS ↗ · Skin and Connective Tissue Diseases Drug: PF-08049820	Phase 2	Authorised	Poland, Czechia, Germany + 2 more
C6461020 - An Interventional Open-Label Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in combination with Different Anticancer Agents in Participants with Advanced Solid Tumors 2025-523526-40-00 · CTIS ↗ · Neoplasms Drugs: PF-08634404, Sigvotatug vedotin	Phase 1	Ongoing	Italy, Spain, France + 1 more
C6461013 - An Interventional Open-label Phase 1b/2 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 as Monotherapy and Combination Therapy in Adult Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma 2025-523525-17-00 · CTIS ↗ · Neoplasms Drugs: Ipilimumab, PF-08634404	Phase 1	Authorised	Spain, Italy, Germany + 1 more
C6461004 - A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER 2025-523522-41-00 · CTIS ↗ · Neoplasms Drugs: Atezolizumab, Carboplatin, Etoposide	Phase 3	Ongoing	France, Italy, Germany + 1 more
C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER 2025-523521-18-00 · CTIS ↗ · Neoplasms Drugs: Bevacizumab, Calcium folinate, Fluorouracil	Phase 3	Ongoing	Spain, Belgium, France + 5 more
C5041018 - A Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis 2025-523100-77-00 · CTIS ↗ · Digestive System Diseases	Phase 2	Ongoing	Finland, Poland, France + 3 more

Drugs in Pfizer trials

91 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 51 more in the trial list above.

Conditions in Pfizer trials

166 conditions

Breast Cancer12 Multiple Myeloma8 Atopic Dermatitis8 Obesity7 Healthy6Pneumococcal Disease6Migraine5 Overweight5Respiratory Syncytial Virus (RSV)5Healthy Adults5Healthy Participants5 Prostate Cancer4 Ulcerative Colitis4 Alopecia Areata4 Hemophilia A4 Hemophilia B4 Carcinoma, Non-Small-Cell Lung4 Non-Small Cell Lung Cancer4Overweight and/or Obesity4Acute Treatment of Migraine4Melanoma3 Colitis, Ulcerative3 NSCLC3 Solid Tumors3

By trial register

Register	Trials	Recruiting
Clinical trials in USA	166	93
Clinical trials in China	73	41
Clinical trials in UK	57	26
Clinical trials in India	29	18
Clinical trials in Ireland	1	0
EU register (CTIS)	15	—

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
AstraZeneca	15
Shengjing Hospital	15
Sichuan Baili Pharmaceutical	12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	12
Hoffmann-La Roche	10
Ruijin Hospital	10
Xijing Hospital	9

Sponsors with the most current trials registered for this condition.

Questions about Pfizer trials

How many clinical trials does Pfizer sponsor?

Pfizer is the lead sponsor of 179 current trials on ClinicalTrials.gov in our USA, China, UK, India and Ireland registers, and 15 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Pfizer trials recruiting?

Yes. 97 of its 179 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Pfizer testing?

Its current trials name 91 drugs and biologicals as interventions. The most frequent are PF-08634404 (16), PF-08653944 (9), Elranatamab (8), Ritlecitinib (8) and 20-valent pneumococcal conjugate vaccine (7). The number in brackets is how many of its trials name each drug.

Does Pfizer have clinical trials in Ireland?

Yes. 1 trial in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) with a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Pfizer clinical trials